echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Pharmaceutical industry performance ice fire two days a number of pharmaceutical companies fell

    Pharmaceutical industry performance ice fire two days a number of pharmaceutical companies fell

    • Last Update: 2021-02-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Tonghuashun data show that as of March 1, a total of 194 A-share biopharmaceutical listed companies issued earnings forecasts. 157 listed companies reported results.
    , 147 listed companies are expected to report year-on-year growth in 2017, with 35 expecting double their results last year, according to the company. Another 47 listed companies experienced varying degrees of decline in performance, of which 24 biopharmaceutical companies experienced a decline of more than 50%.in an interview with Securities Daily, Shi Lichen, founder of
    third-party pharmaceutical service platform Maxcomlai, said that in 2017, the performance of pharmaceutical industry enterprises in general, in 2018, with the full implementation of the two-vote system, especially in the health care control fees, drug tenders, secondary bargaining and other combination of boxing policies, drug prices are expected to further reduce, non-therapeutic drug use will be further restricted, corporate performance will be even worse.
    , an industry source told reporters that the future of the pharmaceutical industry ice and fire phenomenon will be more obvious. High-quality enterprises will get better and better, and poor enterprises will be phased out.114 pharmaceutical companiesperformance growth of more than 30%
    affected by the policy, performance differentiation has become a major feature of the overall performance of biopharmaceutical enterprises in recent years.
    data show that 114 biopharmaceutical listed companies achieved more than 30% performance growth. The four listed companies of Berry Gene, Tianme Pharmaceuticals, Furen Pharmaceuticals and Zhifei Bio are expected to grow by more than 1000%. In addition, Le mei Pharmaceuticals, Yabao Pharmaceuticals, Chengzhi shares, Bei lu pharmaceutical industry, Lizhu Group and other listed companies are expected to increase performance by more than 100%. Sea King Bio, Yifan Pharmaceuticals, Jincheng Pharmaceuticals, Guangyuyuan, Pharmaceutical Stone Technology, American Health and other listed companies pharmaceutical companies are expected to increase performance by more than 50%.
    of the 114 listed companies mentioned above, there are 17 chemical API enterprises, 23 chemical preparation enterprises, 16 biological products companies, 13 medical service enterprises, 17 medical device enterprises, 7 pharmaceutical commercial companies and 21 Chinese pharmaceutical enterprises.
    among the listed companies with declining performance, Boji Pharmaceuticals, Jiuan Medical, Watson Bio, Jiaying Pharmaceuticals, Chiyama Pharmaceuticals, Zhongyuan Concord expect a 100% decline in performance. Taiji Group, Lesin Medical, Guo Nong Technology, Haihong Holdings, Enlighten Guhan and other listed companies are expected to see a 50% decline in performance.
    2017, the performance of several listed companies was affected by the impact of medical insurance fees and drug tenders, especially in the form of restricted use of complementary drugs.
    , according to reporters combing, including the red-day pharmaceutical industry, Yuheng pharmaceutical industry and other multi-drug enterprises, including some products due to health insurance fee pressure, product sales were affected.
    note that policy changes have also led to a new round of value remodeling in the pharmaceutical market. Enterprises with innovative research and development capabilities and rich product lines are sought after by the market.pharmaceutical companies said marketing costs are rising
    and in response to market changes, they are constantly carrying out marketing reforms and increasing their spending.
    , for example, yuheng Pharmaceuticals expects net profit attributable to shareholders of listed companies to fall by 56% in 2017. Yu Heng Pharmaceuticals said that during the reporting period, the company's operating profit, total profit, net income attributable to listed companies, basic earnings per share fell significantly, mainly due to the impact of the two-vote policy, the company adjusted the sales model, sales costs rose sharply.
    the 2017 Results Express, the company reported operating income of RMB26,958.7 million, which was basically flat compared to the same period in 2016, while net profit attributable to shareholders of listed companies was RMB16,496.4 million, down 65.09 percent from the same period in 2016. One of the reasons for the change in performance is: during the reporting period, the pharmaceutical market deepened reform, the company overcomes the hospital drug proportion control, medical insurance control fees, drug tender secondary bargaining and other comprehensive factors, increase the construction of marketing network, actively carry out marketing, continue to promote and implement development goals, sales costs increased by more than 20 million yuan compared to the same period in 2016.
    increase in the cost of sales is also Longjin Pharmaceuticals. Longjin Pharmaceuticals expects the company to achieve operating income of RMB30,444.77 million in 2017, up 36.14% YoY, and net profit attributable to shareholders of listed companies of RMB35,037.3 million, down 61.51% YoY. In response to the decline in performance, Longjin Pharmaceuticals explained that in 2017 the company in response to a new round of successful regional demand for distributors, accelerated the nationwide promotion of fine marketing to deep distribution transformation efforts. However, the initial sales costs increased significantly, which had a negative impact on the company's profits, while the company's investment in the secondary development of existing products and the development of new drugs continued to increase, and the cost of development expenses led to an increase in management expenses, resulting in a significant decline in net profit attributable to shareholders of listed companies compared to the same period in 2016. (Securities Daily)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.